IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer cells exhibit resistance to apoptosis and uncontrolled proliferation.
• p53 is a critical tumor suppressor, regulating apoptosis and preventing neoplastic transformation.
• Mutations in isocitrate dehydrogenase 1 (IDH1) are common in certain cancers, like glioma.

Purpose of the Study:

• To investigate the mechanism by which oncogenic IDH1 mutants inhibit p53 expression.
• To elucidate the role of 2-hydroxyglutarate (2-HG) in p53 regulation in IDH1-mutated cancers.
• To explore the therapeutic implications of targeting the IDH1-p53 axis.

Main Methods:

• Investigated the effect of oncogenic IDH1 R132H/R132Q mutants on p53 expression in mouse embryonic fibroblast cells.
• Assessed the role of 2-hydroxyglutarate (2-HG) in stabilizing hypoxia-inducible factor-2α (HIF-2α).
• Analyzed the expression of miR-380-5p and its impact on p53.
• Correlated p53 and IDH1 R132H protein levels in human glioma samples.

Main Results:

• Oncogenic IDH1 R132H/R132Q mutants significantly inhibit p53 expression, mediated by 2-HG production.
• 2-HG stabilizes HIF-2α, leading to increased expression of miR-380-5p, a negative regulator of p53.
• Restoring p53 expression in IDH1 R132Q-mutated cells reduced proliferation and enhanced apoptosis sensitivity.
• A negative correlation was observed between p53 protein levels and IDH1 R132H levels in human glioma tissues.

Conclusions:

• IDH1 mutations down-regulate p53 through the 2-HG/HIF-2α/miR-380-5p pathway.
• Impaired p53-mediated apoptosis contributes to tumorigenesis driven by IDH1 mutants.
• Targeting this pathway may offer therapeutic strategies for IDH1-mutated cancers.